Anticorps Monoclonal anti-MGMT

MGMT Monoclonal Antibody for FC, IF, WB, ELISA

Hôte / Isotype

Mouse / IgG2a

Réactivité testée

Humain et plus (1)

Applications

WB, IF, FC, ELISA

Conjugaison

Non conjugué

Publications

2

CloneNo.

1H2C9

N° de cat : 67476-1-Ig

Synonymes

Homo sapiens (Human), MGMT

---

Galerie de données de validation

• 

  WB analysis using 67476-1-Ig

  Various lysates were subjected to SDS PAGE followed by western blot with 67476-1-Ig (MGMT antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 67476-1-Ig

  Various lysates were subjected to SDS PAGE followed by western blot with 67476-1-Ig (MGMT antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. The membrane was stripped and reblotted with HRP-conjugated GAPDH Monoclonal antibody (HRP-60004) as loading control.

• 

  IF Staining of HepG2 using 67476-1-Ig

  Immunofluorescent analysis of (4% PFA) fixed HepG2 cells using MGMT antibody (67476-1-Ig, Clone: 1H2C9 ) at dilution of 1:100 and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L).

• 

  FC experiment of Jurkat using 67476-1-Ig

  1X10^6 Jurkat cells were intracellularly stained with 0.4 ug Anti-Human MGMT (67476-1-Ig, Clone:1H2C9) and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

---

Applications testées

• Résultats positifs en WB: cellules U2OS, cellules A549, cellules HeLa, cellules HepG2, cellules Jurkat, cellules LNCaP, cellules MCF-7, cellules MOLT-4, cellules Raji
• Résultats positifs en IF: cellules HepG2,
• Résultats positifs en cytométrie: cellules Jurkat,

Dilution recommandée

• Western Blot (WB): WB : 1:5000-1:50000
• Immunofluorescence (IF): IF : 1:50-1:500
• Flow Cytometry (FC): FC : 0.40 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• IF: See 2 publications below

Informations sur le produit

67476-1-Ig cible MGMT dans les applications de WB, IF, FC, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain, souris
• Hôte / Isotype: Mouse / IgG2a
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: MGMT Protéine recombinante Ag29936
• Nom complet: O-6-methylguanine-DNA methyltransferase
• Masse moléculaire calculée: 22 kDa
• Poids moléculaire observé: 22 kDa
• Numéro d’acquisition GenBank: BC000824
• Symbole du gène: MGMT
• Identification du gène (NCBI): 4255
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

MGMT is the primary vehicle for cellular removal of alkyl lesions from the O-6 position of guanine and the O-4 position of thymine. While key to the maintenance of genomic integrity, MGMT also removes damage induced by alkylating chemotherapies, inhibiting the efficacy of cancer treatment [PMID:23065697].MGMT is the primary mechanism for the removal of alkylation damage from the O-6 position of guanine [PMID: 17482892]. The O-6 position of guanine is one of several positions in DNA bases to which alkyl groups are attached in SN1 alkylation reactions, and this repair has been well-characterized in mammalian cells and via MGMT homologs in bacteria and Archaea.[PMID: 10767620]

Publications

Species	Application	Title
human	IF	Nucleic Acids Res; KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response.; Authors - Mingming Yang
mouse	IF	Cancer Discov; Targeting Microglial Metabolic Rewiring Synergizes with Immune Checkpoint Blockade Therapy for Glioblastoma; Authors - Zengpanpan Ye